Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why are you upset? The filing isn't late. The deadline hasn't even passed. Are you one that critiques a book or movie without having read or watched it?
The last time they filed late, they filed after the investor conference call, which began at 4:30 p.m. and lasted about an hour. They cut it too close and missed the EDGAR cut-off time. Stupid mistake, but not likely one that's going to be repeated.
If you're really concerned over something that hasn't happened yet, you still have time to unload your shares. Plenty of buyers willing to pick them up cheap.
How exactly are you voting him off the island?
Cut-off time for EDGAR system is 5:30 p.m. EST. As long as it is entered and accepted in their system by that time, it will be considered filed today, even if it doesn't show up in the filings until tomorrow. The submission date of the filing will indicate today.
The last time they filed late, they missed the EDGAR deadline by 5 minutes, according to Russell Miller. There has been a lot of speculation that the late filing resulted in the DTC chill that followed, but there was some idiot posting on the board that TD Ameritrade was reporting the DTC chill and it was impacting their ability to trade the stock. This was a day before the filing was considered late.
It's not late until it's late. I'm confident it will be filed on time.
Hard to say for sure, but it look like he's using MANF. Research using MANF is fine, as long as they don't try to bring a treatment to market without going through Amarantus first.
Things would be much clearer if they'd just call it CDNF if that's what they're using, instead of using MANF or MANF2 interchangeably. It might be understood among researchers, but it tends to create confusion among investors and laymen in general.
I'm happy we have a CEO who makes the effort to answer shareholder questions and clear up the confusion. No worries here... NONE. Full speed ahead, Amarantus.
Is there even an issue with licenses/patents here? By Saarma's own words, CDNF doesn't infringe on MANF's patent and MANF doesn't infringe on CDNF's patent. So why does Saarma keep referring to CDNF as MANF2? Is he intentionally trying to cause disruption among Amarantus shareholders, creating an issue and state of fear over patent protection where none exists? If he simply referred to his molecule as CDNF, would there be all this concern over patent infringement?
Remember the fear created by some over the Supreme Court case involving Myriad Genetics? They sold their entire AMBS positions over what "might" happen. At the time Gerald clearly stated he and his advisors didn't feel that case had anything to do with MANF. As it turns out, it didn't.
This may be nothing but fear mongering caused by Saarma's use of the term MANF in describing his research. I feel confident in the company's ability to monitor any research done concerning MANF, and to take the appropriate action if the company's patents are infringed upon. No shareholder should let discussions on a message board, whether accurate or not, influence their decision as a shareholder. If the company feels their patents are infringed upon, they will take the appropriate action.
If Saarma's research into CDNF generates treatments that benefits patients afflicted with various diseases, more power to him. If he infringes on Amarantus patents in doing so, that's for the courts to decide. As with the Myriad case, I'm not going to concern myself much over what "might" happen.
Amarantus Appoints Dr. Charlotte Keywood Chief Medical Officer of Its Therapeutics Division
Press Release: http://ir.stockpr.com/amarantus/company-news/detail/1214
LinkedIn profile: http://uk.linkedin.com/pub/charlotte-keywood/6/135/1a9
Glad to help. Now you can enjoy a McDonald's Happy Meal with your friends with the $20 you won. Perhaps they can offer some tips on how to read between wolfing down their fries. And perhaps one of them might even know the difference between the 10-K and 10-K/A filings. The educational opportunities abound for you on this fine culinary outing. Best of luck. LMAO
It's clear you don't understand the difference between a 10-K filing and a 10-K/A (amended) filing. The 10-K filing was on 4/17/13. The amended filing was on 4/26/13.
I'll paint you a picture, since you didn't bother to click the link I provided in my reply to your post.
http://www.sec.gov/Archives/edgar/data/1424812/000114420413022383/0001144204-13-022383-index.htm
Maybe this will make it clearer for you. Focus on the areas in the RED boxes. Is it clear for you now?
Yeah, I figured you'd try to cover up your ignorance with another implied claim of "fishing" for a response. Lame excuse for being ignorant of the facts.
I'm glad the picture worked for you. Sometimes a picture is the only thing that gets through to some of the less intelligent of our species.
Wrong, Solantey. Your memory needs some refreshing.
Last year the 10-K was filed on 4/16/13 shortly after the investor conference call. They missed the EDGAR cut-off time of 5:30 p.m. for acceptance on the due date of 4/16. As a result, the filing date was reported as 4/17 and considered late. Here's the filing with the date and time of acceptance, and it clearly shows it wasn't 4/26.
http://www.sec.gov/Archives/edgar/data/1424812/000114420413022383/0001144204-13-022383-index.htm
This was all covered in great detail in a post I made, giving clear evidence the chill was already in effect before the late filing occurred.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87827990
The chill had nothing to do with the late filing. Gerald made a statement to that effect around the time the chill was lifted. Yet a number of uninformed investors continue to make that claim. It's surprising that you make this claim since you were the first investor who reported the trading restriction on this board before the filing dealing had passed.
JP, we're cool. I know we have the same ultimate goal, regardless of differing opinions on the best way to get there.
JP, I inquired about the possibility of a hostile takeover over a year ago. Gerald gave me the same response about the 1 billion authorized shares. Do I believe he lied to me? No, I believe at the time they felt they'd get a partnering deal which would provide the needed capital to fund the company's objectives going forward, until such time LymPro would be on the market and generating revenues.
As more advisors were brought on, the strategy seemed to change to developing the asset to increase it's potential value, and partnering later. This decision directly impacted dilution by having to issue more shares to raise capital for continued research and operations. Part of the dilution was used to clean up the balance sheet in late 2012 position the company for what lay ahead.
So in my view, this was a trade-off, a change of strategy, not an intentional lie to shareholders. Assuming a partnership offer was on the table back then, it was likely a small percentage of the amounts they're negotiating today. Accepting the offer then would have eliminated the need for some of the dilution we've seen, but could also have short-changed investors in the longer term by having more of the potential revenue stream going to the partner instead of to the company. We're talking YEARS of revenue streams being lost to outside partners. In that regard, the additional dilution to raise capital was likely seen as the better alternative, even if it resulted in upsetting some investors who focused primarily on that single metric.
I'm not drinking the company Kool-Aid. I simply don't get bent out of shape over a single aspect of what's happening, such as dilution, without considering the reasons and the alternative options that were available. And I do believe every decision being made is with the longer-term outlook and what's best for the company and its shareholders. In my view, their decisions reflect that. If I ever feel that's not the case, I'll be moving out of my position. But until that time I am confident in my own DD, and that provided by others I respect, and I'm not going to sit here and second guess every decision they make, because I don't have and never will have all the facts that fed into their decision. Gerald seems very willing to discuss the strategy of their decisions, and I admire that, and it's one of the reasons I remain a "loyal long investor".
JP, I'm aware this was John's article, but it appears on Gerald's blog site. Perhaps my wording implied I thought Gerald wrote it. Regarding the comment about watching the share price like a hawk, I was referring to longs on this board in general, including myself. Are you telling me you don't check the share price daily? I know I"m guilty of it. For a long-term investor, this seems rather hawkish. Why are we watching it daily, if we are long-term in mindset?
Perhaps I did miss your point, but sophomoric response? Really? I think most investors would do well to remember the historical truth and wisdom in the phrase Rome wasn't built in a day. Maybe I should substitute Amgen wasn't built in a day, as that would be more fitting here. That's what I keep reminding myself when I start to get frustrated over the company's progress. It helps me to put this company's progress into historical context with my own expectations. Yes, I'd prefer to make a fortune sooner rather than later. We all would. But that's unrealistic. A lot of us claim to be long investors yet act sometimes like we're short-term traders. There are too many companies on OTC that seem to have overnight success once certain news is released. Perhaps that's our fate as well, or perhaps our fate is a slow rise in share price as this story develops. Either way, we win as investors, but perhaps not in sync with our expectations.
Let me point out something I've noticed from a number of longs here. When the company is leading up to news, most of the posts are filled with excitement and anticipation, yet after the news hits and it's not quite what was hoped for, then begins a period of posts where doubts are expressed, where timelines start to be questioned, where suggestions are made that perhaps things might not be panning out as previously announced, where perhaps the potential partner might not be interested after all. Every time I see it I think to myself... perhaps that investor wasn't as solid in their beliefs as they've previously claimed. All the fantastic DD done by some of these investors, and then the doubts begin that undermine their own great DD.
I'm not suggesting it's wrong to express doubts. I am saying that I don't share those doubts, and while I was hoping a partner would have been revealed with Gerald's LymPro update, my faith isn't shaken by the fact no partnership has been announced thus far. I believe both John and Gerald know the potential value of PhenoGuard as well as LymPro, and will not only take the time to search for the best deal, but the right partner to carry them forward. Perhaps that's J & J regarding PhenoGuard, perhaps not. There's a lot of companies capable of moving PhenoGuard forward besides J & J, in my opinion. While they're likely the front runner in any discussions, it would be foolish to make them the only candidate. If there are negotiations between multiple partners, I can certainly see this taking many months (i.e., more than 5 months). My post mentioned a year as sort of an upper boundary before I start having doubts. I certainly didn't imply that I'd wait multiple years for something such as PhenoGuard to move forward with a partnership, especially given what was stated in John's article. That's unrealistic too.
If my post struck a nerve, that wasn't my intention. Our views obviously differ on expectations and timelines. I continue to admire your DD and efforts to keep investors informed, as I do others here. I just don't share some of your concerns over a period of 5 months with no updates on a single asset of the company.
I think some of us are just itching to make our millions on this investment. It's understandable how frustration can set in. Been there myself, and have to keep telling myself Rome wasn't built in a day, and neither was Amgen. I have to make myself focus on things besides the share price, and remind myself I'm still close to double my purchase price over the last 16 months. If I have expectations beyond that at present, it's my own fault.
The company is close to commercializing their first product, and moving forward on several others. They are executing on their business plan, and if there's one thing I'm truly confident about, it's that the timeline will never match up with my expectations or hopes. But I truly believe success will happen here.
I don't know, JP. For me, 5 months seems to be a bit soon to be growing concerned over whether a partnership is in the works. Ask me a year after the announcement if nothing has come to fruition.
I believe Gerald's blog post was to inform us that PhenoGuard is another asset that has great value to outside interests, not necessarily that a partnership would be inked soon. The company already has enough irons in the fire at present, it wouldn't surprise me if PhenoGuard is classified as a medium-term asset and will be moved to near-term after more milestones are achieved on some of the more critical assets, like LymPro and Eltoprazine.
That doesn't mean I'm not excited about the possibilities of PhenoGuard as a revenue-generating machine, especially if we get up-front license fees and royalties on any discovery that leads to revenues. Hopefully we won't have to wait another 5 months to hear something on any progress.
Just my thoughts. Exciting times ahead, but not for those who watch the share price daily like a hawk. It will make one age prematurely.
Also supported by his response to my questions last week.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=99805470
I understand your point, Risk, but I also believe the lack of media coverage is not a clumsy oversight as some have suggested, but a strategic part of their plan to launch LymPro. Yes, it has negatively impacted share price, which is what we as investors focus on. But the company is focusing on much more than near-term share price in this process. They have to weigh options and strategies that we don't even consider, based on analysis and recommendations of their advisors. I believe they will launch media coverage in a big way, when the time is right. While we might not agree with that decision, we also don't know what other factors have gone into their decision. We can speculate, but our opinions might prove to be short-sighted at this stage.
You're right, all of this will become clear in the coming months. Perhaps we should all take a break and come back in a few months. The day-to-day market response to news and updates continues to drive long-term investors nuts.
My pleasure, Jimmy. I wish you the best with your investment. There's a very bright future ahead for the company and its investors.
No, I don't believe Amarantus is turning into a fraud. It seems clear to me that Gerald and his advisors have kept LymPro off the media radar for a reason, most likely to ensure the scientific data is rock solid and unquestionable before announcing this to the world. If you remember, the LymPro test was on a shelf at Provista due to lack of funding to move it forward. Amarantus acquired the license and spent the money to bring the development to the current state. Provista (now MemoryDX) will get 9% royalty payments from LymPro revenues when it is commercialized.
Just because Dr. Stern gives his opinion a blood test is 5-10 years away doesn't tell the whole story. He may truly be unaware of it because he's not involved in the LymPro testing going on with other researchers at Boston U. He may in fact know of it and may even be involved with it, but under a NDA and can't discuss it with the media until such time Amarantus decides the time is right. Or perhaps he doesn't know of it because the other researchers are under NDAs.
If Amarantus is a fraud, then they've certainly pulled the wool over the eyes of a lot of leading experts in the biotech world who have come on board over the last year. I can't see this caliber of people getting involved with any company unless they've done their own due diligence and verified for themselves the company, the product and the claims are all legitimate. Participating in a fraud would destroy their reputation and have a major negative impact on their careers.
While this is a board for intelligent discussion, there are some here who deliberately post lies and misinformation in an effort to undermine the stock price or the company. The board is a great source of info and due diligence performed by investors, but everyone should think for themselves. Some of us actually try to provide accurate, verifiable info to counter the misinformation and to help others form valid opinions on this company as an investment.
Personally, I believe it's an investment with fantastic potential. I've invested over $300K. That's REAL.
I emailed Ms. Kotz, the author of the article, and let her know about LymPro. Who knows? Maybe we'll see a follow-up story. Can't hurt to try to get the word out to those writing such articles who are unaware of how close we are to market.
Anyone who has to resort to using multiple screen names to express their views is a moron. No one should pay any attention to anything stated by morons.
I'm sorry if the truth hurts, morons.
And P/E is based on earnings, not revenues. Although I expect the gross margin to be rather high for LymPro, it will still be a percentage of revenue. Whatever the calculated value of share price turns out to be, it is likely to be many orders of magnitude higher than the current share price. And that's on LymPro alone, and doesn't even include the valuation added by MANF, Eltoprazine, or any other products in the Amarantus pipeline.
Serious wealth is coming to those with the foresight and wisdom to see what's unfolding, to take as large a position as their situation and risk tolerance allows, and to wait for the story to unfold. Betting the rent or mortgage payment and fretting over the daily price fluctuations is a complete waste of time. You might as well bet that money on a crap shoot in the alley behind your local bar. All IMO, of course.
Sorry, but you are misinformed about the specifics of late filing and the extension period.
AMBS was NOT delisted from OTCBB last year because of late filing. There was a DTCC "chill" which resulted in some brokerage houses (TD Ameritrade in particular) to not trade the stock until the chill was lifted months later. The chill was for issues between the company and their stock transfer agent. It had nothing to do with the late filing. The timing was coincidental.
This was well documented here, and I was right in the middle of it as I'm a TD Ameritrade client. The chill order was already in effect before the filing deadline on April 16, 2013, the same day the company held a conference call with investors.
If you look at posts on that day, you will see some investors were already affected by the chill order, and yet the company didn't miss the filing deadline of 4:30 p.m. EST until later that afternoon, filing the 10-K literally 5 minutes late and missing the EDGAR cut-off for filing that day.
Today's filing was for a filing extension date. It was NOT a late filing any more than filing an extension on your tax return results in a late filing penalty as long as you file by the extended filing date. It won't count against the company as a late filing.
Today's update agrees with what Gerald stated in an email to me last week.
You're right, hardly anyone outside the medical and pharma community are aware that LymPro even exists. But following today's update, it appears the company will not pursue the kind of media coverage we've seen recently until all the data is in and it's verified rock solid.
Think about it. What followed shortly after the media frenzy over the recent AD blood test being developed at Georgetown University? We started seeing articles questioning the accuracy and some of the reported claims. I don't believe Gerald and his advisors are as clueless about the marketing of this diagnostic test as some would suggest. I believe when they start alerting the media, it will be supported by rock-solid testing and that will convince the naysayers it's a solid product and one that will change how the world diagnoses and treats AD.
NT 10-K Notification of Late Filing
http://www.sec.gov/Archives/edgar/data/1424812/000114420414019586/v373307_nt10k.htm
From Investopedia:
http://www.investopedia.com/terms/s/sec-form-nt-10k.asp
The Annual Report (10-K) is due today.
A lot of stupid investors unloading their shares this morning, unable to see past making a quick profit on April's mortgage payment. They will regret their short-sightedness. I firmly believe that. Those of us with vision are going to experience enormous wealth in this investment.
Gerald tweeted Friday morning he was looking forward to giving shareholders a LymPro update on Monday. Previously he had stated he would update shareholders on Lympro soon.
This is expected by many to be a significant update, and we're hoping the news is good enough to drive the share price higher, possibly much higher. In any case, we should have a much better idea of the strategy for commercialization later this year.
Check out the videos of Adam Simon, CEO of Cerora and an Amarantus advisor, at the following link. Amazing stuff, and a perfect partner for Amarantus diagnostics strategy for brain disorders.
http://www.cerora.com/movies.php
Here is the content of DocStock's deleted post. It was pulled from a cached page and is now posted over on Yahoo. I'm posting the content of the original message below, but have removed the parts that violated TOS and resulted in the message being deleted. I bolded the part that everyone seems curious about.
Yes, we have the "luxury" of an exchange, but that doesn't mean an insurance company must accept someone who is lying to them about their health status. Refusing to take a blood test to verify existing conditions is akin to refusing to take a breath analysis when requested by the police officer who has pulled you over and has reason to believe you are intoxicated. Refusal to comply is considered guilt. Refusal to take a blood test for a LTC policy will be considered high risk and will result in the highest premiums.
The insurance company may be required by law to offer you a policy, but the law doesn't require them to go bankrupt in the process of issuing LTC policies to everyone who has AD. The costs for such a policy will be high. Nobody wins if the insurance companies fail due to excessive costs.
Classic example of "the pot calling the kettle black" (a person being guilty of the very thing of which they accuse another)...
I think Gerald would enjoy helping to expose the barking little dog that continues to claim that "Gerald told me ____ today". Are you afraid Gerald's response will counter some claims that you've spoken on the phone with him recently?
I will ask, and post a reply if I get one. Then everyone will know the truth about whether your recent phone chats with Gerald actually occurred as claimed.
I have a life. I also enjoy exposing liars on message boards for companies I'm invested in. BTW, I have proof of my claimed holdings, ready to post. Are you ready to support your claims with proof?
Perhaps someone should learn how to write correctly so there are no perceived issues with alleged reading comprehension.
Damn, only 112,000 shares? I thought with all the spamming effort you put into this you were a big player. I guess I assumed wrong. Reminds me of one of the "know what you own" leaders who put an enormous amount of effort into DD and getting others to invest... and then we find out he only had about $2,000 invested.
Not slamming small investors. We all come to this investment with different levels of risk and financial assets to invest, but damn, only 112,0000 shares for all that effort seems like a waste of time. Why am I even conversing with such a minor-league player in this game? LOL
I'm feeling great now that the "unfortunate soul" is done selling. Thanks for letting us know that was the reason. Anything more you can share on specifics? Why would someone have to dump so many shares like that? It created a great buying opportunity for those with cash available, perhaps the last one we'll ever see at those levels since the LymPro update on Monday might be a major one.
There are social media links at the bottom of every page on the Amarantus web site.
Also links on the CEO blog page.
http://www.thechairmansblog.com/amarantus-bioscience/blogs/